دورية أكاديمية
Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models.
| العنوان: | Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models. |
|---|---|
| المؤلفون: | Patel N; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA., Kommineni N; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA., Surapaneni SK; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA., Kalvala A; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA., Yaun X; Department of Chemical and Biomedical Engineering, Florida State University, Tallahassee, FL, USA; The National High Magnetic Field Laboratory, Florida State University, Tallahassee, FL, USA., Gebeyehu A; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA., Arthur P; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA., Duke LC; Department of Biomedical Sciences, Florida State University College of Medicine, 1115 West Call Street, Tallahassee, FL, USA., York SB; Department of Biomedical Sciences, Florida State University College of Medicine, 1115 West Call Street, Tallahassee, FL, USA., Bagde A; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA., Meckes DG Jr; Department of Biomedical Sciences, Florida State University College of Medicine, 1115 West Call Street, Tallahassee, FL, USA., Singh M; College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA. Electronic address: mandip.sachdeva@gmail.com. |
| المصدر: | International journal of pharmaceutics [Int J Pharm] 2021 Sep 25; Vol. 607, pp. 120943. Date of Electronic Publication: 2021 Jul 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3476 (Electronic) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam, Elsevier/North-Holland Biomedical Press. |
| مواضيع طبية MeSH: | Breast Neoplasms*/drug therapy , Cannabidiol* , Extracellular Vesicles* , Triple Negative Breast Neoplasms*/drug therapy, Cell Line, Tumor ; Doxorubicin ; Female ; Humans |
| مستخلص: | Extracellular Vesicles (EVs) were isolated from human umbilical cord mesenchymal stem cells (hUCMSCs) and were further encapsulated with cannabidiol (CBD) through sonication method (CBD EVs). CBD EVs displayed an average particle size of 114.1 ± 1.02 nm, zeta potential of -30.26 ± 0.12 mV, entrapment efficiency of 92.3 ± 2.21% and stability for several months at 4 °C. CBD release from the EVs was observed as 50.74 ± 2.44% and 53.99 ± 1.4% at pH 6.8 and pH 7.4, respectively after 48 h. Our in-vitro studies demonstrated that CBD either alone or in EVs form significantly sensitized MDA-MB-231 cells to doxorubicin (DOX) (*P < 0.05). Flow cytometry and migration studies revealed that CBD EVs either alone or in combination with DOX induced G1 phase cell cycle arrest and decreased migration of MDA-MB-231 cells, respectively. CBD EVs and DOX combination significantly reduced tumor burden (***P < 0.001) in MDA-MB-231 xenograft tumor model. Western blotting and immunocytochemical analysis demonstrated that CBD EVs and DOX combination decreased the expression of proteins involved in inflammation, metastasis and increased the expression of proteins involved in apoptosis. CBD EVs and DOX combination will have profound clinical significance in not only decreasing the side effects but also increasing the therapeutic efficacy of DOX in TNBC. (Copyright © 2021 Elsevier B.V. All rights reserved.) |
| References: | Cancer Res. 2011 Mar 1;71(5):1742-51. (PMID: 21343398) J Exp Clin Cancer Res. 2011 Sep 26;30:87. (PMID: 21943236) Cancer Res. 1989 Jul 15;49(14):3976-84. (PMID: 2660984) Am J Public Health. 2020 Oct;110(S3):S294-S299. (PMID: 33001729) Cell Commun Signal. 2020 Feb 28;18(1):33. (PMID: 32111215) PLoS One. 2014 Jan 28;9(1):e87092. (PMID: 24489842) Sci Rep. 2017 Sep 21;7(1):12064. (PMID: 28935932) Toxicol Appl Pharmacol. 2020 Aug 15;401:115112. (PMID: 32540278) Int J Pharm. 2020 Jan 25;574:118916. (PMID: 31811927) Biomark Res. 2019 Apr 4;7:8. (PMID: 30992990) Eur J Pharm Biopharm. 2021 Jan;158:172-184. (PMID: 33220423) Cancer Res. 2004 Jul 1;64(13):4514-22. (PMID: 15231661) J Control Release. 2021 May 10;333:374-390. (PMID: 33798666) Cancers (Basel). 2020 Oct 30;12(11):. (PMID: 33143283) Oncol Rep. 2013 Jan;29(1):219-25. (PMID: 23129177) J Mater Chem B. 2019 Apr 21;7(15):2421-2433. (PMID: 32255119) Stem Cells. 2020 Jan;38(1):15-21. (PMID: 31381842) Iran Biomed J. 2015;19(2):69-75. (PMID: 25864810) J Control Release. 1998 Jan 2;50(1-3):71-8. (PMID: 9685874) Sci Rep. 2020 Oct 21;10(1):17954. (PMID: 33087811) Eur J Pharmacol. 2019 Jan 15;843:251-259. (PMID: 30481497) J Control Release. 2018 Dec 10;291:184-195. (PMID: 30367922) Cancer Sci. 2018 Aug;109(8):2364-2374. (PMID: 29908100) J Vis Exp. 2012 Jan 09;(59):e3037. (PMID: 22257828) Pain. 2019 Jan;160(1):210-223. (PMID: 30188455) Sci Rep. 2016 Apr 12;6:23978. (PMID: 27068479) Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):12-19. (PMID: 30419312) Drug Deliv. 2016 May;23(4):1232-41. (PMID: 26701717) Asian Pac J Cancer Prev. 2014;15(20):8617-22. (PMID: 25374178) J Cell Sci. 2009 Jan 15;122(Pt 2):207-14. (PMID: 19118213) Endocr Relat Cancer. 2015 Oct;22(5):831-40. (PMID: 26229035) Drugs. 2000 Dec;60(6):1303-14. (PMID: 11152013) J Virol. 2018 Feb 12;92(5):. (PMID: 29212935) Adv Exp Med Biol. 2020;1245:163-176. (PMID: 32266658) Cancers (Basel). 2020 Jul 21;12(7):. (PMID: 32708138) Glia. 2020 Mar;68(3):561-573. (PMID: 31647138) Sci Rep. 2018 Aug 16;8(1):12295. (PMID: 30115982) Cell Mol Life Sci. 2015 Feb;72(4):659-71. (PMID: 25336151) PLoS One. 2013 Dec 31;8(12):e84256. (PMID: 24391924) Curr Drug Metab. 2016;17(3):206-26. (PMID: 26651971) Breast Cancer Res Treat. 2011 Aug;129(1):37-47. (PMID: 20859676) J Biol Eng. 2019 Sep 14;13:74. (PMID: 31534477) J Pharm Sci. 2007 Feb;96(2):312-9. (PMID: 17051591) Front Pharmacol. 2018 Nov 26;9:1365. (PMID: 30534073) Genet Mol Res. 2015 May 25;14(2):5621-9. (PMID: 26125760) Phytother Res. 2019 Aug;33(8):2083-2093. (PMID: 31250491) Trends Cell Biol. 2013 Dec;23(12):620-33. (PMID: 23958396) Biomed Res Int. 2019 Aug 18;2019:6458237. (PMID: 31531362) J Control Release. 2021 Jan 10;329:894-906. (PMID: 33058934) J Microencapsul. 1998 Jul-Aug;15(4):485-94. (PMID: 9651870) Breast Cancer Res. 2020 Jun 9;22(1):61. (PMID: 32517735) Oncotarget. 2017 Feb 14;8(7):11555-11565. (PMID: 28030791) J Cell Biochem. 2017 Oct;118(10):3237-3248. (PMID: 28262977) Mol Pharm. 2015 Apr 6;12(4):1105-20. (PMID: 25661724) Biol Chem. 2013 Jan;394(1):1-15. (PMID: 23241589) Stem Cell Res. 2020 Jul 1;47:101888. (PMID: 32688331) J Vis Exp. 2015 Jan 17;(95):50974. (PMID: 25650897) Chem Phys Lipids. 2019 Nov;224:104707. (PMID: 30521787) Eur J Surg Oncol. 1995 Dec;21(6):607-8. (PMID: 8631404) Front Bioeng Biotechnol. 2020 Jun 24;8:640. (PMID: 32671039) Int J Biol Sci. 2017 Nov 1;13(11):1387-1397. (PMID: 29209143) J Control Release. 2021 Feb 10;330:15-30. (PMID: 33278480) J Control Release. 2012 Aug 10;161(3):927-32. (PMID: 22580111) Lancet. 2012 Apr 28;379(9826):1591-601. (PMID: 22440947) Epilepsy Behav. 2019 Jun;95:131-136. (PMID: 31048098) Mol Cancer Ther. 2007 Nov;6(11):2921-7. (PMID: 18025276) Jpn J Clin Oncol. 2004 Mar;34(3):124-30. (PMID: 15078907) J Hematol Oncol. 2015 Jul 10;8:83. (PMID: 26156517) Adv Clin Chem. 2016;74:103-41. (PMID: 27117662) Oncogene. 2021 Feb;40(7):1284-1299. (PMID: 33420367) J Clin Invest. 2016 Apr 1;126(4):1208-15. (PMID: 27035812) Eur Rev Med Pharmacol Sci. 2016;20(6):1115-22. (PMID: 27049265) Cancer Res. 2008 Jan 15;68(2):339-42. (PMID: 18199524) Mol Cancer Ther. 2011 Jan;10(1):90-103. (PMID: 21220494) Life Sci. 2007 Mar 20;80(15):1415-9. (PMID: 17303175) J Control Release. 2017 Sep 28;262:104-117. (PMID: 28736264) Br J Clin Pharmacol. 2013 Feb;75(2):303-12. (PMID: 22506672) Nat Rev Cancer. 2012 May 04;12(6):436-44. (PMID: 22555283) Biochem Eng J. 2018 Mar 15;131:39-46. (PMID: 29736144) Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26. (PMID: 15459662) Technol Cancer Res Treat. 2018 Jan 1;17:1533033818763450. (PMID: 29681222) Cell Death Differ. 2019 Dec;26(12):2594-2606. (PMID: 30903102) Mol Oncol. 2015 Apr;9(4):906-19. (PMID: 25660577) Cancer Lett. 2009 Nov 18;285(1):6-12. (PMID: 19442435) Int J Cancer. 2006 Apr 15;118(8):1922-9. (PMID: 16287078) Exp Cell Res. 1997 Jan 10;230(1):111-20. (PMID: 9013713) Int J Mol Sci. 2020 Mar 31;21(7):. (PMID: 32244518) Nature. 2020 Oct;586(7829):E19. (PMID: 33057216) Pharmaceutics. 2019 Mar 25;11(3):. (PMID: 30934535) Nat Rev Cancer. 2003 Oct;3(10):745-55. (PMID: 14570037) Anticancer Res. 2018 Oct;38(10):5831-5835. (PMID: 30275207) Ann Pharmacother. 2021 Jul;55(7):921-931. (PMID: 33070624) PLoS One. 2015 Feb 06;10(2):e0117111. (PMID: 25658913) Curr Oncol Rep. 2006 Mar;8(2):96-103. (PMID: 16507218) Cancer Res. 2001 Jul 15;61(14):5562-9. (PMID: 11454708) Mol Ther. 2015 May;23(5):812-823. (PMID: 25868399) Methods Mol Biol. 2017;1660:303-317. (PMID: 28828667) Cell Death Differ. 2005 Aug;12(8):1021-30. (PMID: 15933741) Immunity. 2019 Jul 16;51(1):27-41. (PMID: 31315034) Cancer Res. 2013 Jun 1;73(11):3470-80. (PMID: 23633491) Breast Cancer Res Treat. 2016 Jun;157(3):489-501. (PMID: 27255534) Eur J Pain. 2016 Jul;20(6):936-48. (PMID: 26517407) J Control Release. 2011 Feb 10;149(3):281-91. (PMID: 20971141) Stem Cells Dev. 2013 Mar 15;22(6):845-54. (PMID: 23002959) Anticancer Res. 2011 Nov;31(11):3799-807. (PMID: 22110202) Nat Rev Cancer. 2005 Mar;5(3):231-7. (PMID: 15738985) Sci Rep. 2017 Mar 16;7:44735. (PMID: 28300219) J Pharm Sci. 2015 Dec;104(12):4417-4426. (PMID: 26372815) Stem Cells Int. 2017;2017:6305295. (PMID: 29410682) J Cancer. 2019 Jun 24;10(17):3926-3932. (PMID: 31417636) Stem Cells Transl Med. 2017 Jan;6(1):51-59. (PMID: 28170176) Yonago Acta Med. 2019 Jun 20;62(2):182-190. (PMID: 31320822) Cancer Prev Res (Phila). 2011 Jan;4(1):65-75. (PMID: 21097714) J Control Release. 2014 Oct 28;192:262-70. (PMID: 25084218) Pharmaceutics. 2020 May 09;12(5):. (PMID: 32397428) Br J Pharmacol. 2005 Apr;144(8):1032-6. (PMID: 15700028) Pharmacol Rep. 2020 Dec;72(6):1627-1644. (PMID: 32720218) Biochem Pharmacol. 2010 Apr 1;79(7):955-66. (PMID: 19914218) Daru. 2019 Dec;27(2):533-539. (PMID: 31317441) Mol Cancer Ther. 2014 Dec;13(12):2955-67. (PMID: 25398831) Int J Nanomedicine. 2012;7:1525-41. (PMID: 22619510) Breast. 2018 Oct;41:34-41. (PMID: 30007266) Mol Cell Biol. 2016 Apr 15;36(9):1383-94. (PMID: 26929200) Carcinogenesis. 2013 Jan;34(1):48-57. (PMID: 23079154) J Natl Cancer Inst. 1993 Feb 17;85(4):292-8. (PMID: 8426373) J Natl Compr Canc Netw. 2021 Mar 10;19(7):797-804. (PMID: 33691275) Eur J Pharm Biopharm. 2020 Sep;154:246-258. (PMID: 32682943) Biotechnol J. 2019 Aug;14(8):e1800716. (PMID: 30945467) J Pharmacokinet Biopharm. 1981 Jun;9(3):245-60. (PMID: 6270295) Int J Pharm. 2015 Jul 15;489(1-2):106-16. (PMID: 25910414) Cancer Sci. 2015 Aug;106(8):1023-32. (PMID: 26041409) Molecules. 2018 Sep 27;23(10):. (PMID: 30262735) Theranostics. 2018 Apr 9;8(10):2739-2751. (PMID: 29774072) Lancet. 2017 Oct 21;390(10105):1833-1842. (PMID: 28855077) Crit Rev Ther Drug Carrier Syst. 2021;38(5):53-97. (PMID: 34375513) J Exp Med. 2019 Jun 3;216(6):1234-1243. (PMID: 31023715) Mol Cancer Res. 2017 Jun;15(6):723-734. (PMID: 28213554) J Virol. 2017 Feb 14;91(5):. (PMID: 27974566) Biochem Eng J. 2021 Apr;168:. (PMID: 33967591) Cancer Manag Res. 2018 Mar 02;10:403-416. (PMID: 29535553) Nanomedicine. 2012 Sep;8 Suppl 1:S21-30. (PMID: 22640908) Anticancer Res. 2019 Feb;39(2):541-548. (PMID: 30711928) |
| معلومات مُعتمدة: | U54 MD007582 United States MD NIMHD NIH HHS |
| فهرسة مساهمة: | Keywords: Cannabidiol; Doxorubicin and triple negative breast cancer; Extracellular vesicles; Sensitization |
| المشرفين على المادة: | 19GBJ60SN5 (Cannabidiol) 80168379AG (Doxorubicin) |
| تواريخ الأحداث: | Date Created: 20210729 Date Completed: 20210922 Latest Revision: 20240403 |
| رمز التحديث: | 20240403 |
| مُعرف محوري في PubMed: | PMC8528640 |
| DOI: | 10.1016/j.ijpharm.2021.120943 |
| PMID: | 34324983 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1873-3476 |
|---|---|
| DOI: | 10.1016/j.ijpharm.2021.120943 |